Thiazolidinedione
Thiazolidinedione 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Diabetes Mellitus, Type 2。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
9 项
已进入 III/IV 期
8 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Chong Kun Dang Pharmaceutical
- Mayo Clinic
- Kyu Chang Won
- Boryung Pharmaceutical Co., Ltd
- Assistance Publique - Hôpitaux de Paris
- Federico II University
- Versailles Hospital
- Emory University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、South Korea、法国、意大利、中国、瑞典、Israel、中国台湾
正在招募患者的 Thiazolidinedione 研究
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
II 期招募中美国NCT06729996A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
不适用招募中South KoreaNCT06627322A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
I 期招募中South KoreaNCT07083388A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
III 期招募中法国NCT05946564GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
IV 期招募中意大利NCT07314684Insulin Regulation of Lipolysis and Lipolysis Proteins
早期 I 期招募中美国NCT03866408Second STOP After Pioglitazone Priming in CML Patients
II 期招募中法国NCT02889003Bioenergetic Effect of Pioglitazone in CLD-PH
II 期招募中美国NCT06336798An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
II 期招募中中国NCT07117630Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
不适用招募中美国NCT02969798Pioglitazone Therapy Targeting Fatigue in Breast Cancer
II 期招募中美国NCT05013255Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
不适用招募中瑞典NCT05501483Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
IV 期招募中South KoreaNCT06399835Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
不适用招募中South KoreaNCT06838286Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
IV 期招募中美国NCT05838287Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
IV 期招募中美国NCT07848191A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.
早期 I 期招募中IsraelNCT05753657A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
IV 期招募中South KoreaNCT06972732Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
IV 期招募中美国NCT06657209SGLT2i, Pioglitazone, and Ketone Production in T2D
I 期招募中美国NCT07053319Prevention of Progression of Prediabetes, Obesity and CV Risk
I 期招募中美国NCT06446531SGLT2i, Pioglitazone, and Ketone Production in T1D
III 期招募中美国NCT07056699The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
II 期招募中中国台湾NCT06528405Quantifying Hepatic Mitochondrial Fluxes in Humans
IV 期招募中美国NCT05305287
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。